Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to participate in the Innovator’s Pitch Challenge at the upcoming Redefining Early Stage Investments (RESI) conference, held digitally June 8-10, 2021.
The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of relevant investors.
Sonic Incytes CEO George Aliphtiras will present VelacurTM, the first handheld 3D liver health assessment solution to tackle the emerging fatty liver disease (NASH) crisis, on June 8.
The RESI conference connects start-ups with early-stage investors and strategic channel partners, who are a fit for their technology and stage of development.
For more information, visit https://resiconference.com/pitch-challenge/.
